• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Relmada Therapeutics Inc.

    2/12/26 9:13:06 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Relmada Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    75955J402

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75955J402


    1Names of Reporting Persons

    Adage Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,270,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,270,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,270,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.82 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    75955J402


    1Names of Reporting Persons

    Robert Atchinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,270,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,270,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,270,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.82 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    75955J402


    1Names of Reporting Persons

    Phillip Gross
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,270,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,270,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,270,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.82 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Relmada Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    2222 Ponce De Leon Blvd, 3rd Floor, Coral Gables, FL, 33134
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock") of Relmada Therapeutics, Inc., a Nevada corporation (the "Company") directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
    (c)Citizenship:

    ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    75955J402
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 73,333,622 shares of Common Stock outstanding as of November 10, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025.
    (b)Percent of class:

    5.82%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adage Capital Management, L.P.
     
    Signature:/s/ Robert Atchinson
    Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
    Date:02/12/2026
     
    Robert Atchinson
     
    Signature:/s/ Robert Atchinson
    Name/Title:Robert Atchinson, individually
    Date:02/12/2026
     
    Phillip Gross
     
    Signature:/s/ Phillip Gross
    Name/Title:Phillip Gross, individually
    Date:02/12/2026
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $RLMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    1/23/2026$8.00Outperform
    Leerink Partners
    12/22/2025$69.00Buy
    Jefferies
    11/19/2025$10.00Neutral → Outperform
    Mizuho
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    More analyst ratings

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on Relmada Therapeutics with a new price target

    Leerink Partners resumed coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/23/26 8:21:07 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Relmada Therapeutics with a new price target

    Jefferies initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $69.00

    12/22/25 8:39:56 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics upgraded by Mizuho with a new price target

    Mizuho upgraded Relmada Therapeutics from Neutral to Outperform and set a new price target of $10.00

    11/19/25 9:00:23 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CA and CO Ence Chuck

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:04 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Relmada Therapeutics Inc.

    SCHEDULE 13G - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/12/26 9:13:06 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Relmada Therapeutics Inc.

    SCHEDULE 13G - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/6/26 4:31:51 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Relmada Therapeutics Inc.

    424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    1/30/26 5:14:28 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

    FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the registrational development pathway for NDV-01 in 2nd-line ref

    1/12/26 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

    Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States CORAL GABLES, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncolo

    12/3/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

    Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of common stock and pre-funded warrants on November 5th to support planned operations into 2028 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NAS

    11/13/25 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    View All

    Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

    Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada's Clinical Advisory Board (CAB) to support the development of NDV-01 for the

    10/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

    Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa

    7/15/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

    SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective June 25, 2025. Dr. Traversa currently serves as CEO of Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, where he has led the company through the advancement of multiple clinical-stage programs and financing events. "We're excited to welcome Sergio to the DIMERx team," said Nikhi

    7/9/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Financials

    Live finance-specific insights

    View All

    Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

    Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of common stock and pre-funded warrants on November 5th to support planned operations into 2028 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NAS

    11/13/25 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

    CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, November 13, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Webcast Access: Click Here A replay of the webcast will b

    11/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

    6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous

    8/7/25 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    11/14/24 9:41:31 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    3/6/24 4:15:42 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/14/24 8:53:47 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care